|
|
|
|
|
|
|
|
Conclusions: Lower dose of weekly topotecan was well tolerated in patients with platinum-resistant ovarian or peritoneal cancer at first relapse, with a favourable hematologic profile. Moreover, antitumor activity was similar to that reported for the standard dose of weekly regimen.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.